12月10日,制药公司uniQure N.V.股价出现了剧烈波动。
盘中,uniQure股价一度飙升超138%,触发熔断。导致其大涨的主要原因是,公司当日获得FDA同意,将正在进行的一项基因疗法研究采取加速审批路径,避免耗时较长的审批步骤。消息一出,多家机构便上调了uniQure的目标股价,看好这一潜在重磅新药的前景。
但在夜盘交易中,uniQure股价出人意料地大跌5.23%。目前尚无公开报道直接解释了其大跌原因,相关消息或已延迟披露。投资者需继续留意后续发展,了解公司基本面以及导致股价剧烈波动的具体原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.